title: Therapeutic potential of interleukin-27 against cancers in preclinical mouse models.
abstract: Since we first reported the antitumor efficacy of IL-27 in 2004, accumulating evidence obtained by several groups using a variety of preclinical mouse models indicates that IL-27 possesses potent antitumor activity against various types of tumors through multiple mechanisms depending on the characteristics of individual tumors without apparent adverse effects.
authors.affiliation: Department of Immunoregulation; Institute of Medical Science; Tokyo Medical University ; Tokyo, Japan.
authors.forename: Izuru
authors.initials: I
authors.lastname: Mizoguchi
authors.affiliation: Department of Immunoregulation; Institute of Medical Science; Tokyo Medical University ; Tokyo, Japan.
authors.forename: Yukino
authors.initials: Y
authors.lastname: Chiba
authors.affiliation: Department of Immunoregulation; Institute of Medical Science; Tokyo Medical University ; Tokyo, Japan.
authors.forename: Jun-Ichi
authors.initials: JI
authors.lastname: Furusawa
authors.affiliation: Department of Immunoregulation; Institute of Medical Science; Tokyo Medical University ; Tokyo, Japan.
authors.forename: Mingli
authors.initials: M
authors.lastname: Xu
authors.affiliation: Department of Immunoregulation; Institute of Medical Science; Tokyo Medical University ; Tokyo, Japan.
authors.forename: Ren
authors.initials: R
authors.lastname: Tsunoda
authors.affiliation: Department of Immunoregulation; Institute of Medical Science; Tokyo Medical University ; Tokyo, Japan.
authors.forename: Kaname
authors.initials: K
authors.lastname: Higuchi
authors.affiliation: Department of Immunoregulation; Institute of Medical Science; Tokyo Medical University ; Tokyo, Japan.
authors.forename: Takayuki
authors.initials: T
authors.lastname: Yoshimoto
keywords: IL-27; TLR3; TRAIL; antitumor; poly(I:C)